NYLIM
DYN icon

New York Life Investment Management’s Dyne Therapeutics DYN Stock Holding History

New York Life Investment Management’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-30,210
Closed -$402K – 1380
2023
Q4 		$402K Sell
30,210
-696
-2% -$6.8K ﹤0.01% 993
2023
Q3 		$277K Sell
30,906
-4,870
-14% -$52.5K ﹤0.01% 1203
2023
Q2 		$402K Sell
35,776
-6,593
-16% -$77.8K ﹤0.01% 995
2023
Q1 		$488K Buy
+42,369
New +$550K 0.01% 749

Other funds holding DYN

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

New York Life Investment Management's DYN Position: Q1 2024 in Review

New York Life Investment Management sold out of Dyne Therapeutics (DYN) in Q1 2024, closing a stake of 30,210 shares — an estimated $402K sold.

New York Life Investment Management first reported a position in DYN in Q1 2023 and held it in 4 quarters. The position peaked at $488K in Q1 2023. 169 funds tracked by Wall St. Rank hold DYN as of Q1 2024.

  • New York Life Investment Management reported no remaining Dyne Therapeutics position as of Q1 2024 after selling out during the quarter.
  • New York Life Investment Management sold 30,210 Dyne Therapeutics shares in Q1 2024, an estimated $402K.
  • New York Life Investment Management first reported a position in Dyne Therapeutics in Q1 2023 and held it in 4 quarters.
  • New York Life Investment Management's Dyne Therapeutics position peaked at $488K in Q1 2023.
  • 169 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2024.

Based on New York Life Investment Management's 13F filing for Q1 2024, filed 6 May 2024.